Seroatlas · Human Serome Atlas

UBE2I

SUMO-conjugating enzyme UBC9

Also known as: UBC9, UBC9_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P63279
Gene: UBE2I
Ensembl: ENSG00000103275
Chromosome: 16
Canonical length: 158 aa
Protein class: Cancer-related genes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins, Transporters
Subcellular location: Nucleoplasm,Nucleoli

OverviewNCBI Gene

The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. Four alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

158 residues, UniProt reviewed canonical sequence.

>P63279|UBE2I
     1  MSGIALSRLA QERKAWRKDH PFGFVAVPTK NPDGTMNLMN WECAIPGKKG TPWEGGLFKL
    61  RMLFKDDYPS SPPKCKFEPP LFHPNVYPSG TVCLSILEED KDWRPAITIK QILLGIQELL
   121  NEPNIQDPAQ AEAYTIYCQN RVEYEKRVRA QAKKFAPS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against UBE2I can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.29
Highest tissue expression: 103 nTPM

Expression across tissuesHPA

Tissue

thymus: 103 nTPM
ovary: 89 nTPM
tonsil: 84 nTPM
bone marrow: 77 nTPM
lymph node: 71 nTPM
adrenal gland: 69 nTPM

Single-cell type

syncytiotrophoblasts: 497 nCPM
oocytes: 493 nCPM
migrating cytotrophoblasts: 366 nCPM
cytotrophoblasts: 365 nCPM
extravillous trophoblasts: 350 nCPM
esophageal basal cells: 307 nCPM

Immune cell

eosinophil: 328 nTPM
memory B-cell: 299 nTPM
basophil: 280 nTPM
total PBMC: 261 nTPM
intermediate monocyte: 257 nTPM
non-classical monocyte: 251 nTPM

Brain region

hypothalamus: 54 nTPM
cerebellum: 52 nTPM
hippocampal formation: 50 nTPM
cerebral cortex: 49 nTPM
basal ganglia: 47 nTPM
midbrain: 45 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.29
gnomAD pLI: 0.96
gnomAD missense Z: 3.1
DepMap mean gene effect: -2.04
DepMap dependency class: pan

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 7% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of UBE2I in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads UBE2I as an antibody target. Whether an autoantibody or antibody against UBE2I could matter depends on whether native UBE2I is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

UBE2I is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label UBE2I as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...